Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723706 · ClinicalTrials.gov registry record
Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 33
- Enrollment target
NCT04723706: Completed study, sponsored by Henry Ford Health System.
NCT04723706 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04723706 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option. Patients after SCT or CART have a variable period of immune deficiency in the post-treatment period. The response to vaccination may affect the outcome of the transplant patients. the immunogenicity of vaccines in this immunosuppressed population is uncertain and variable. HSCT and CAR-T recipients are in a COVID-19 high-risk group and conferring immunity by vaccination at the earliest effective timepoint is desirable. At present, the immunogenicity and efficacy of SARS-CoV-2 vaccines in immune-impaired patients including autologous and allogeneic HSCT recipients is unknown. Furthermore, the impact of GvHD and IST on SARS-CoV-2 vaccine immunogenicity is unknown. the investigators aim to evaluate the vaccination response to COVID vaccines after SCT and CART
Interventions
- DIAGNOSTIC_TEST COVID-19 serology IgG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2024-01-02 |
What the finished NCT04723706 record still lists
NCT04723706 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 serology IgG is the first listed.
NCT04723706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04723706 about?
NCT04723706 is a clinical study titled "Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients". For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option. Patients after SCT or CART have a variable period of immune deficiency in the post-treatment period. The response to vac...
What is the current status of trial NCT04723706?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2021-03-19. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT04723706?
The interventions under investigation include: COVID-19 serology IgG (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04723706?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI